Tag: Multiple myeloma
New Phase I Study with SGN-CD48A in Relapsed or Refractory Multiple...
Multiple myeloma is an incurable hematologic malignancy formed by malignant or transformed plasma cells in which the cancerous plasma cells can crowd out healthy...
Promising Preclinical Results Show Antibody Effectively Targets CD74 in Lymphoma and...
Two studies presented at the annual meeting of the American Society of Hematology (ASH), held December 9 - 12, 2017, showed frequent expression of...
Phospholipid Drug Conjugates: Novel Therapeutics Show Promising Results in Multiple Myeloma
While many chemotherapeutic agents are available to treat cancer, they come with the disadvantage of damaging healthy, normal cells in the body. This damage...
Data Confirms STRO-001 Eradicates B-Cell Hematologic Malignancies and Prolongs Survival
STRO-001, an antibody-drug conjugate or ADC targeting the CD74 cell surface protein in hematologic B-cell malignancies, being developed by Sutro Biopharma, has shown to...
Phase I Trial of SGN-CD352A in Relapsed or Refractory Multiple Myeloma...
This week the first patient enrolled in a multi-center phase I clinical trial of SGN-CD352A for the treatment of patients with relapsed or refractory...
Antibody-drug Conjugate Targeting CD46 Eliminates Multiple Myeloma Cells
Authors: Sherbenou DW , Aftab BT , Su Y, Behrens CR , Wiita A, Logan AC , Acosta-Alvear D, Hann BC , Walter...
INSIGHT-MM Study Designed to Advance Real-world Understanding of Multiple Myeloma
In late Augustus 2016 Takeda Oncology announced that the INSIGHT-MM, the company's global non-interventional, observational multiple myeloma study, is now enrolling patients. The study...
Cutting-Edge Science: Personalized Drug Screening for Multiple Myeloma
In the decades old "war" against cancer, scientist are increasingly developing ore and better ways to help doctors address the unmet medical needs of...
Oxis Biotech and MultiCell Immunotherapeutics Sign Development Agreements
Oxis Biotech Inc. (Tampa, Florida, 33609)* and MultiCell Immunotherapeutics, Inc. (Woonsocket, RI 02895) announced the execution of a definitive licensing and development agreement for the development of antibody-drug...
